Biostem Technologies Inc
OTC:BSEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biostem Technologies Inc
OTC:BSEM
|
US |
|
Sika Interplant Systems Ltd
BSE:523606
|
IN |
|
SPS Commerce Inc
NASDAQ:SPSC
|
US |
|
M
|
Marmaris Altinyunus Turistik Tesisleri AS
IST:MAALT.E
|
TR |
|
Standex International Corp
NYSE:SXI
|
US |
|
First of Long Island Corp
NASDAQ:FLIC
|
US |
|
Polisan Holding AS
IST:POLHO.E
|
TR |
|
Chobi Co Ltd
KRX:001550
|
KR |
|
U
|
Uniphos Enterprises Ltd
NSE:UNIENTER
|
IN |
|
Oncology Institute Inc
NASDAQ:TOI
|
US |
|
Waga Energy SA
PAR:WAGA
|
FR |
|
Genus Prime Infra Ltd
BSE:532425
|
IN |
|
B
|
Borregaard ASA
SWB:BO4
|
NO |
|
K
|
Kmc Properties ASA
OSE:KMCP
|
NO |
|
Refex Industries Ltd
NSE:REFEX
|
IN |
|
S
|
SMIFS Capital Markets Ltd
BSE:508905
|
IN |
|
L
|
Lizen JSC
VN:LCG
|
VN |
Biostem Technologies Inc
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
Revenue: Q4 revenue was $10.1 million, roughly flat sequentially from $10.5 million but down from $22.7 million year‑ago.
Hospital pivot: Acquisition of BioTissue surgical and wound assets (closed Jan 21, 2026) materially diversifies BioStem toward hospital, ASC and HOPD channels and away from heavy reliance on physician office Medicare reimbursement.
Clinical data: DFU randomized trial showed clear superiority of the company's BioREtain product versus standard of care; VLU top‑line results expected mid‑2026 and full DFU analysis to be published soon.
Q1 outlook & cash: Management expects Q1 revenue of $5.0–$6.0 million; cash was $29.5 million at end of Q4 and approximately $16 million after the BioTissue close, with runway into late Q3 unless additional financing is secured.
Margins & manufacturing: Acquired products carry ~60% gross margin under a 12‑month supply agreement that includes a 23% cost‑plus markup; internal manufacturing historically >85% margin and company expects >80% margin for acquired products after tech transfer.
One‑time charge: Q4 operating expense spike to $17.3 million driven largely by an $8.8 million allowance for potentially uncollectible receivables from distributor Venture Medical (under appeal in many cases).
Integration & commercialization: Company is integrating >25 direct reps + >30 independent agents, plans to expand to at least 40 direct reps, pursue medical education, payer coverage expansion and a product roadmap including a BioREtain dry launch in Q2 2026 and a device pending 510(k).
Audit & listing progress: KPMG is completing 2024 and 2025 audits in advance of a planned NASDAQ uplisting; Jodi Ungrodt joined the board as Audit Committee Chair.
